
Feb 5 (Reuters) - CVS Health Corp CVS.N:
CVS HEALTH HELPS CUSTOMERS ACCELERATE BIOSIMILAR ADOPTION THROUGH FORMULARY CHANGES - SUPPORTING AFFORDABLE OPTIONS FOR OSTEOPOROSIS CARE
CVS HEALTH CORP: EFFECTIVE APRIL 1, 2026, CVS CAREMARK WILL BEGIN OFFERING OSTEOPOROSIS BIOSIMILARS OSPOMYV AND STOBOCLO
CVS HEALTH CORP: EFFECTIVE APRIL 1, 2026, CVS CAREMARK WILL ALSO BEGIN OFFERING GENERIC TERIPARATIDE, BONSITY, AND TYMLOS